Evidence map›Paper›PMID 40385354›Full record

ArticleFrontiers in endocrinology2025

Developing a congenital hyperinsulinism prioritized research agenda: a patient-driven international collaborative research network.

Tai L S Pasquini, Indraneel Banerjee, Henrik Thybo Christesen, Louise S Conwell, Antonia Dastamani, Diva D De Leon, Sarah E Flanagan, David Gillis, Jennifer M Kalish, Katherine Lord and 7 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tai L S PasquiniCongenital Hyperinsulinism International, Glen Ridge, NJ, United States.
Indraneel BanerjeeDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Henrik Thybo ChristesenSteno Diabetes Centre, University of Southern Denmark, Department of Clinical Research, Hans Christian Andersen Children's Hospital, Odense, Denmark.
Louise S ConwellDepartment of Endocrinology and Diabetes, Queensland Children's Hospital and Children's Health Queensland, Greater Brisbane Clinical School, Medical School, University of Queensland, Brisbane, QLD, Australia.
Antonia DastamaniDepartment of Paediatric Endocrinology and Diabetes, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Diva D De LeonCongenital Hyperinsulinism Center and Division of Endocrinology and Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Sarah E FlanaganDepartment of Clinical and Biomedical Science, University of Exeter Medical School, Exeter, United Kingdom.
David GillisDivision of Pediatric Endocrinology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Jennifer M KalishDivision of Human Genetics at the Children's Hospital of Philadelphia and the Departments of Pediatrics and Genetics at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Katherine LordCongenital Hyperinsulinism Center and Division of Endocrinology and Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Mahlet MesfinCongenital Hyperinsulinism International, Glen Ridge, NJ, United States.
Jennifer SchmittCongenital Hyperinsulinism International, Glen Ridge, NJ, United States.
Senthil SenniappanDepartment of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, United Kingdom.
Charles A StanleyCongenital Hyperinsulinism Center and Division of Endocrinology and Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Paul S ThorntonCongenital Hyperinsulinism Center, Division of Endocrinology, Cook Children's Medical Center, Fort Worth, TX, United States.
David ZangenDivision of Pediatric Endocrinology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Julie RaskinCongenital Hyperinsulinism International, Glen Ridge, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Congenital Hyperinsulinism (HI) is a rare disease that causes severe and recurrent hypoglycemia due to dysregulated insulin secretion. HI is the most frequent cause of severe, persistent hypoglycemia in newborns and children. Disease management is focused on preventing the neurological consequences associated with hypoglycemic brain injury; however, treatment is complex, often suboptimal, and places a large burden on families and individuals living with HI. Congenital Hyperinsulinism International (CHI) is an international patient organization that received a grant from the Chan Zuckerberg Initiative to establish the CHI Collaborative Research Network (CRN), a collaborative body to accelerate research for HI. Assessment process: Stakeholder groups relevant to HI, including individuals living with HI, families, researchers, clinicians, nurses, and industry partners, were identified to join the CRN and work together to create a prioritized research agenda (PRA) to systematically rank research priorities. CRN members worked across 7 workstream groups through a structured process to brainstorm gaps and corresponding solutions to formalize the HI PRA. Actionable recommendations: A total of 362 gaps were identified across research, infrastructure, knowledge, and funding. All groups identified the need for an HI Natural History Study; therefore, this item was identified as a priority that would automatically be placed on the finalized list. Other top gaps identified in the PRA addressed preventing brain damage and the need to increase awareness and understanding related to the role of early and effective diagnosis in preventing brain damage. Discussion: The formation of the CRN and the development of the PRA have already led to new collaborations, which are fundamental to progress. The PRA process allowed individuals to come to a consensus on the critical needs and to chart short- and long-term approaches to fill the gaps. CRN members continue to meet regularly in working groups focused on special projects to fill gaps identified as high priority by the PRA. Through this active and multidimensional alliance, the CRN is re-imagining the future for people living with HI by improving outcomes through more timely and accurate diagnosis, more effective and less burdensome treatments, more easily obtainable expert care, and better tools to manage HI.

Indexed as

Biomedical ResearchCongenital HyperinsulinismHumansInternational Cooperationcollaborative research networkcongenital hyperinsulinismhypoglycemiapatient advocacyprioritized researchrare diseases

Identifiers

PMID40385354
PMCPMC12082039

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.